Patients with type 2 diabetes who switched to tirzepatide rather than escalating their dulaglutide dosage had greater weight ...

USA: A recent study has highlighted the potential benefits of tirzepatide for overweight and obese adults with type 1 ...

Previous studies have shown improved kidney function with other drugs in the same class but this trial is the first to assess tirzepatide's impact on kidney and cardiovascular outcomes in people ...

NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c ...

Both are chronic conditions that progressively worsen over time. Tirzepatide targets two receptors in order to shrink fat cells and reduce the impacts that enlarged fat cells have on heart and ...

Obesity was tied with an increased risk of developing 16 health outcomes, a large longitudinal study showed. Risks correlated ...

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...

GPs will be able to prescribe Mounjaro weight-loss injections from late June to ‘prioritised patient cohorts’ set out by NHS ...

April 1 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ingredient in its popular ...

Tirzepatide — the main active ingredient in ... You may qualify for a prescription for Mounjaro if you have type 2 diabetes, have a BMI of at least 27, and are having difficulty losing weight.

While the weight loss results were impressive across the group, the cost and side effects remain important barriers for ...